Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;247(4):310-316.
doi: 10.1177/15353702211067718. Epub 2022 Jan 19.

Innovative approaches for treatment of osteosarcoma

Emel Rothzerg  1   2 , Abigail L Pfaff  2   3 , Sulev Koks  2   3
Affiliations
Review

Innovative approaches for treatment of osteosarcoma

Emel Rothzerg et al. Exp Biol Med (Maywood). 2022 Feb.

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor, which usually occurs in children and adolescents. It is generally a high-grade malignancy presenting with extreme metastases to the lungs or other bones. The etiology of the disease is multifaceted and still remains obscure. A combination of surgery and chemotherapy has played a major role in the treatment of OS over the past three decades, and consequently, the overall survival rates for the disease have remained unchanged. Therefore, there is an urgent need to employ new comprehensive analyses and technologies to develop significantly more informative classification systems, with the aim of developing more effective and less toxic therapies for OS patients. This review discusses the existing knowledge of OS therapy and potential methods to develop novel therapeutic agents for the disease.

Keywords: Osteosarcoma; sarcoma; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Lee DY, Staddon AP, Shabason JE, Sebro R. Phase I and phase II clinical trials in sarcoma: implications for drug discovery and development. Cancer Med 2019;8:585–92 - PMC - PubMed
    1. Constantinidou A, Pollack S, Loggers E, Rodler E, Jones RL. The evolution of systemic therapy in sarcoma. Expert Rev Anticancer Ther 2013;13:211–23 - PubMed
    1. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003;3:685–94 - PubMed
    1. Rothzerg E, Ho XD, Xu J, Wood D, Martson A, Maasalu K, Koks S. Alternative splicing of leptin receptor overlapping transcript in osteosarcoma. Exp Biol Med 2020;245:1437–43 - PMC - PubMed
    1. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment – where do we stand? A state of the art review. Cancer Treat Rev 2014;40:523–32 - PubMed

Publication types